Lantheus (NASDAQ:LNTH) Issues FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $6.60-6.70 for the period, compared to the consensus EPS estimate of $7.07. The company issued revenue guidance of $1.50-1.52 billion, compared to the consensus revenue estimate of $1.52 billion. Lantheus also updated its FY 2024 guidance to 6.600-6.700 EPS.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on LNTH shares. SVB Leerink lifted their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an outperform rating in a research report on Thursday, July 11th. Truist Financial dropped their price target on Lantheus from $141.00 to $135.00 and set a buy rating on the stock in a research report on Thursday. JMP Securities dropped their target price on Lantheus from $130.00 to $125.00 and set a market outperform rating on the stock in a report on Thursday. Mizuho upped their price objective on shares of Lantheus from $90.00 to $100.00 and gave the company a buy rating in a research note on Friday, May 3rd. Finally, StockNews.com downgraded Lantheus from a buy rating to a hold rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $119.00.

Lantheus Trading Down 1.0 %

Lantheus stock opened at $97.59 on Friday. Lantheus has a one year low of $50.20 and a one year high of $126.89. The company’s fifty day moving average price is $92.18 and its two-hundred day moving average price is $73.12. The company has a market capitalization of $6.78 billion, a price-to-earnings ratio of 14.90 and a beta of 0.51. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.55.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. During the same period in the previous year, the business posted $1.40 earnings per share. The firm’s revenue was up 22.5% on a year-over-year basis. On average, analysts forecast that Lantheus will post 6.46 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the sale, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the sale, the director now directly owns 23,340 shares of the company’s stock, valued at $1,848,294.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,799 shares of company stock worth $3,769,262. 1.50% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.